Market On Close Imbalance: $445M To Sell-Side

– Reuters 

– Reuters 

Total
0
Shares
Related Posts
Read More

CG Oncology Announces Data From The Phase 3 BOND-003 Study Evaluating The Efficacy And Safety Of Cretostimogene Monotherapy, Demonstrated 75.2% Complete Response Rate In High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today at 4:30pm EDT

CGON